View Financial HealthIntegrated BioPharma 配当と自社株買い配当金 基準チェック /06Integrated BioPharma配当金を支払った記録がありません。主要情報n/a配当利回り-1.2%バイバック利回り総株主利回り-1.2%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • Oct 29Integrated BioPharma, Inc., Annual General Meeting, Dec 01, 2025Integrated BioPharma, Inc., Annual General Meeting, Dec 01, 2025. Location: 225 long avenue, hilside, new jersey 07205., United Statesお知らせ • Oct 29Integrated BioPharma, Inc., Annual General Meeting, Dec 02, 2024Integrated BioPharma, Inc., Annual General Meeting, Dec 02, 2024. Location: at the companys executive offices, located at 225 long avenue, new jersey 07205, hillside, United Statesお知らせ • Oct 28Integrated BioPharma, Inc., Annual General Meeting, Nov 27, 2023Integrated BioPharma, Inc., Annual General Meeting, Nov 27, 2023, at 09:00 US Eastern Standard Time. Location: 225 Long Avenue, Hillside New Jersey United States Agenda: To elect three Class II directors for a three-year term to serve until the 2026 Annual Meeting of Stockholders; to provide a non-binding, advisory vote on executive compensation; to ratify the appointment of the company’s independent auditor for the fiscal year ending June 30, 2024; and to consider the transaction of such other business as may properly come before the Annual Meeting or any adjournment thereof.お知らせ • Oct 28Integrated BioPharma, Inc., Annual General Meeting, Nov 28, 2022Integrated BioPharma, Inc., Annual General Meeting, Nov 28, 2022, at 09:00 US Eastern Standard Time. Location: 225 Long Avenue, Hillside Jersey City New Jersey United States Agenda: To elect one class iii director for a three-year term to serve until the 2025 annual meeting of stockholders; to ratify the appointment of the company's independent auditor for the fiscal year ending June 30, 2023; and the transaction of such other business as may properly come before the annual meeting or any adjournment thereof.お知らせ • Jun 22Integrated Biopharma, Inc. Announces Change in DirectorsIntegrated BioPharma, Inc. announced Mr. Carl DeSantis has resigned as a Class I Director from the Company's Board of Directors and Mr. Damon DeSantis, has been elected to serve as a Class I Director to fill the vacancy left by Mr. Carl DeSantis. Damon currently serves as a board member of MacPherson's, the large employee-owned distributor of creative materials and art supplies in North America and since August 2021, Celsius Holding, Inc. (CELH), maker of the leading global fitness drink, CELSIUS. His corporate business interests continue with ownership, direct investment, and board membership in a variety of private businesses in the hospitality, financial services, automotive, spirits and cannabis industries. Previously, Damon served as Chief Executive Officer of Rexall Sundown Nutritional Company, a former Nasdaq 100 company until 2001 as well as a board member of the company. Rexall Sundown was in the business of developing, manufacturing, packaging, marketing, and distributing nutritional products of over 2800 SKUs to wholesalers, distributors, retailers in the US and worldwide. Damon is the son of Carl DeSantis, one of the principal shareholders of INBP and former Board member.お知らせ • Nov 10Integrated Biopharma, Inc. Appoints Eric Friedman as Director and to the Audit Committee of the Board of DirectorsOn November 4, 2020, Eric Friedman was appointed as a Director of Integrated BioPharma, Inc. to fill the vacancy on the Company's Board of Directors. Mr. Friedman will serve as a Class III Director and his term will expire in 2022. Mr. Friedman has over three decades of accounting and financial operations experience, including controller, chief financial officer and a partner with the accounting firm Shachat & Simpson, CPA's. Mr. Friedman served as the Controller of RES Realty LLC from 2019 to 2020, was an independent consultant from 2016 to 2019 and the Controller of W & E Sales Co. Inc, from 2011 to 2016. Mr. Friedman was also appointed to the Audit Committee of the Board of Directors.決済の安定と成長配当データの取得安定した配当: INBPの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: INBPの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Integrated BioPharma 配当利回り対市場INBP 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (INBP)n/a市場下位25% (US)1.4%市場トップ25% (US)4.3%業界平均 (Personal Products)3.2%アナリスト予想 (INBP) (最長3年)n/a注目すべき配当: INBPは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: INBPは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: INBPの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: INBPが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/23 02:19終値2026/06/23 00:00収益2026/03/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Integrated BioPharma, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Oct 29Integrated BioPharma, Inc., Annual General Meeting, Dec 01, 2025Integrated BioPharma, Inc., Annual General Meeting, Dec 01, 2025. Location: 225 long avenue, hilside, new jersey 07205., United States
お知らせ • Oct 29Integrated BioPharma, Inc., Annual General Meeting, Dec 02, 2024Integrated BioPharma, Inc., Annual General Meeting, Dec 02, 2024. Location: at the companys executive offices, located at 225 long avenue, new jersey 07205, hillside, United States
お知らせ • Oct 28Integrated BioPharma, Inc., Annual General Meeting, Nov 27, 2023Integrated BioPharma, Inc., Annual General Meeting, Nov 27, 2023, at 09:00 US Eastern Standard Time. Location: 225 Long Avenue, Hillside New Jersey United States Agenda: To elect three Class II directors for a three-year term to serve until the 2026 Annual Meeting of Stockholders; to provide a non-binding, advisory vote on executive compensation; to ratify the appointment of the company’s independent auditor for the fiscal year ending June 30, 2024; and to consider the transaction of such other business as may properly come before the Annual Meeting or any adjournment thereof.
お知らせ • Oct 28Integrated BioPharma, Inc., Annual General Meeting, Nov 28, 2022Integrated BioPharma, Inc., Annual General Meeting, Nov 28, 2022, at 09:00 US Eastern Standard Time. Location: 225 Long Avenue, Hillside Jersey City New Jersey United States Agenda: To elect one class iii director for a three-year term to serve until the 2025 annual meeting of stockholders; to ratify the appointment of the company's independent auditor for the fiscal year ending June 30, 2023; and the transaction of such other business as may properly come before the annual meeting or any adjournment thereof.
お知らせ • Jun 22Integrated Biopharma, Inc. Announces Change in DirectorsIntegrated BioPharma, Inc. announced Mr. Carl DeSantis has resigned as a Class I Director from the Company's Board of Directors and Mr. Damon DeSantis, has been elected to serve as a Class I Director to fill the vacancy left by Mr. Carl DeSantis. Damon currently serves as a board member of MacPherson's, the large employee-owned distributor of creative materials and art supplies in North America and since August 2021, Celsius Holding, Inc. (CELH), maker of the leading global fitness drink, CELSIUS. His corporate business interests continue with ownership, direct investment, and board membership in a variety of private businesses in the hospitality, financial services, automotive, spirits and cannabis industries. Previously, Damon served as Chief Executive Officer of Rexall Sundown Nutritional Company, a former Nasdaq 100 company until 2001 as well as a board member of the company. Rexall Sundown was in the business of developing, manufacturing, packaging, marketing, and distributing nutritional products of over 2800 SKUs to wholesalers, distributors, retailers in the US and worldwide. Damon is the son of Carl DeSantis, one of the principal shareholders of INBP and former Board member.
お知らせ • Nov 10Integrated Biopharma, Inc. Appoints Eric Friedman as Director and to the Audit Committee of the Board of DirectorsOn November 4, 2020, Eric Friedman was appointed as a Director of Integrated BioPharma, Inc. to fill the vacancy on the Company's Board of Directors. Mr. Friedman will serve as a Class III Director and his term will expire in 2022. Mr. Friedman has over three decades of accounting and financial operations experience, including controller, chief financial officer and a partner with the accounting firm Shachat & Simpson, CPA's. Mr. Friedman served as the Controller of RES Realty LLC from 2019 to 2020, was an independent consultant from 2016 to 2019 and the Controller of W & E Sales Co. Inc, from 2011 to 2016. Mr. Friedman was also appointed to the Audit Committee of the Board of Directors.